[Rituximab therapy for relapsing IgG4-autoimmune pancreatitis and cholangitis - a case report]

Area of Science:

• Gastroenterology
• Immunology
• Hepatology

Background:

• Autoimmune pancreatitis (AIP) and autoimmune cholangitis (AIC) are chronic inflammatory conditions.
• Standard therapies include steroids and immunosuppressants like azathioprine and mycophenolate mofetil.
• These conditions can lead to significant complications such as bile duct strictures.

Observation:

• A patient with relapsing AIP and AIC experienced multiple disease flares over three years despite conventional therapy.
• The patient required repeated endoscopic interventions for bile duct strictures.
• Conventional immunosuppressive therapy failed to achieve long-term disease control.

Findings:

• Initiation of therapy with the monoclonal CD20 antibody, Rituximab, led to complete cessation of steroid treatment.
• The patient achieved and maintained clinical remission following Rituximab therapy.
• Rituximab demonstrated efficacy in managing refractory autoimmune pancreatitis and cholangitis.

Implications:

• Rituximab represents a potential therapeutic advancement for patients with severe or relapsing AIP and AIC.
• This case highlights the utility of targeted B-cell depletion in managing autoimmune gastrointestinal and hepatobiliary diseases.
• Further research into Rituximab's role in AIP and AIC is warranted to establish its broader clinical utility.